Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology
Melbourne (Australia) and Indianapolis | 25 May 2023
June 21, 2023, at The Yale Club, New York City
The Company will showcase its urologic pipeline, development of novel therapeutics, imaging agents and technologies that aim to harness the power of targeted radiation at every step of the patient journey
Telix today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT.
Institutional investors, analysts and company guests are cordially invited to attend the session, which will feature an overview of the Company’s growth strategy and product pipeline for the detection and treatment of urological cancers.
Speakers will include members of the Telix leadership team, including Managing Director and Group CEO Dr Christian Behrenbruch and U.S.-based executives, Chief Medical Officer Dr Colin Hayward and Telix Americas CEO, Kevin Richardson. The program will focus on Telix’s vision for the field of urology building from its first commercial product Illuccix® for prostate cancer imaging, its follow-on imaging agent for the urology market, TLX250-CDx and the Company’s investigational prostate (prostate specific-membrane antigen, or PSMA-targeting) and renal (carbonic anhydrase IX, or CAIX-targeting) therapy programs.
The event will also feature key opinion leaders in urology and nuclear medicine to discuss the clinical utility and opportunity for Telix’s investigational products.
Key Opinion Leaders
Dr Brian Shuch
Brian Shuch, MD, is the Director of the UCLA Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research. He completed his urology training at UCLA followed by a Urologic Oncology Fellowship at the National Cancer Institute. He is an accomplished surgeon (open/laparoscopic/robotic surgery and percutaneous ablations) and clinical/translational researcher. He serves in leadership positions within various kidney cancer research organizations such as SWOG, NCI Renal Task Force, Kidney Cancer Association, and the SUO. Dr Shuch runs a translational research program with over 160 peer-reviewed publications including primary research published in prestigious journals such as Nature, Nature Genetics, PNAS, JCO, and Clinical Cancer Research. He was a lead investigator on Telix’s ZIRCON Phase III study of TLX250-CDx in clear cell renal cell carcinoma, which reported positive results in November 2022.
Dr Scott T. Tagawa
Scott T. Tagawa, MD, MS, FACP, is a New York-based Professor of Medicine and Urology. Dr Tagawa’s research focuses on clinical and translational investigations in genitourinary tumors and thrombosis in malignancy. Additionally, he specializes in drug development and theranostics in prostate cancer. He is a Fellow of the American Society of Clinical Oncology (ASCO).
Advance registration is required for this event. Please RSVP through this link to attend.
Please register here for the webcast.
Note: This event is for qualified institutional investors and analysts.